

ASX ANNOUNCEMENT

CARDIOCEL® IN SPOTLIGHT AT INTERNATIONAL CONFERENCES

- **Prof Christian Brizard presents CardioCel® valve study data at AATS**
- **CSIRO to present CardioCel® platform for stem cells**

Brisbane, Australia, 6th May 2013

Allied Healthcare Group (ASX: AHZ) today announced key peer reviewed presentations of two key studies. Both studies, which show the exceptional performance of CardioCel® in heart valve repair and stem cell growth, have been presented to surgeons and scientists gathered at key international conferences.

Melbourne-based Professor Christian Brizard presented data from the heart valve reconstruction study at the American Association of Thoracic Surgeons (AATS) mitral conclave meeting in New York on 3 May 2013.

This study demonstrated CardioCel's® superiority over autologous pericardium. CardioCel® was also shown to regenerate native heart valve tissue whilst providing beneficial mechanical properties that preserve valvular function over time, importantly without calcification. The study demonstrated significant valvular tissue regeneration around the CardioCel® implant.

"The presentation last week to a full auditorium of leading heart surgeons in the US highlighted the significant unmet need CardioCel® can provide in the future treatment of heart defects that require tissue repair and reconstruction including repairing heart valves," said Allied Healthcare Group Managing Director Lee Rodne.

"The presentation of this important data at key international conferences also plays an important part in Allied's strategy for raising the awareness of the product globally."

In April, the CSIRO also presented the findings from the stem cell seeding study with CardioCel® at the Society for Biomaterials Meeting in Boston. Allied announced the preliminary findings from this study in January this year. CSIRO is expecting to present the data in September at the European Biomaterials Society Meeting in Madrid.

"The powerful, peer reviewed, data on CardioCel® provides a further depth of support for the anti-calcification and tissue regeneration benefits that CardioCel® will give surgeons in the repair and reconstruction of heart defects," said Bob Atwill, Group Executive and Regenerative Medicine Division CEO at Allied Healthcare Group.

Allied Healthcare Group is pursuing marketing approval for CardioCel® via a CE Mark in Europe and 510 (K) in the US as part of its global launch of the product. CardioCel® is currently being used by Australian surgeons in Brisbane and Melbourne under the Authorised Prescriber Scheme (APS) and recently announced investigator initiated trial.

The abstract for the presentation by Professor Brizard can be found at the following link:

<http://aats.org/mitral/abstracts/2013/39.cgi>



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

www.alliedhealthcaregroup.com.au

For more information, please contact:

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454

Bob Atwill, Group Executive and Regenerative Medicine Division CEO
Tel: +61 448 778 880

Media:
Shevaun Cooper
Buchan Consulting
+61 39866 4722
scooper@buchanwe.com.au

About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from Research & Development through Clinical Development as well as Sales, Marketing and Distribution.

Allied Healthcare Group is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential like Herpes and Human Papilloma virus.

Further information on the Company can be found on www.alliedhealthcaregroup.com.au.

Allied's Regenerative Medicine Division

Allied's regenerative tissue engineering technology started as a research program in in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT[®] Tissue Engineering Process. The lead programme CardioCel[®] has successfully completed a number of animal studies and a Phase II human clinical trial. CardioCel[®] is a cardiovascular patch used to repair paediatric heart deformities. These deformities range from routine "Hole in the Heart" operations to major vessel outflow tract repairs. The CardioCel[®] patch may also be used to repair leaking heart valves in paediatric patients. CardioCel[®] has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration*, suggesting that CardioCel[®] facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

www.alliedhealthcaregroup.com.au

The division is based on the patented ADAPT[®] Tissue Engineering Process as a platform technology to produce implantable tissue patches for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT[®] technology is used to process animal derived tissues to produce unique implantable tissue patches that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post implantation. This technology has the potential for medical professionals to use regenerative products instead of synthetic products currently used in soft tissue repair.

* Körbling & Estrov, 2003. Adult Stem Cells for Tissue Repair — A New Therapeutic Concept? NEJM Volume 349:570-582, August 7, 2003, Number 6



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace
Perth Western Australia 6000

PO Box 6879 East Perth
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

www.alliedhealthcaregroup.com.au